Jung Hee Lee

7435822, Oct 14, 2008

Feb 2, 2005

11/048976

John R. Carson - Norristown PA, US
Jung S. Lee - McLean VA, US

Janssen Pharmaceutica N.V. - Beerse

C07D 401/00
C07D 405/00
C07D 409/00
C07D 411/00
C07D 413/00

546125

This invention is directed to 3-(diheteroarylmethylene)-8-azabicyclo[3. 2. 1] octane and 3-((aryl)(heteroaryl)methylene)-8-azabicyclo[3. 2. 1] octane derivatives useful as δ-opioid, μ-opioid, or δ-opioid and μ-opioid receptor receptor modulators. Depending on their agonist or antagonist effect, the compounds are useful analgesics, immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

7482935, Jan 27, 2009

Oct 28, 2003

10/696263

Jung Kook Lee - Manassas VA, US

G08B 23/00
G08B 1/08
A61B 5/00

3405731, 3405737, 34053911, 34053912, 34053914, 600549, 128903, 128923

The present application discloses a a baby health monitoring device comprising a skin temperature sensor connected to a microprocessor for mathematically converting the sensed temperature to corrected skin temperature; a movement sensor; a display screen for indicating condition of baby; and a means for communicating with a computer.

7884131, Feb 8, 2011

Nov 21, 2005

11/284790

Linda Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Baltimore MD, US
Jung Lee - McLean VA, US
Mary Van Elswyk - Longmont CO, US

Martek Biosciences, Corporation - Columbia MD

A61K 31/22
C07C 59/00
C07C 57/00

514549, 514165, 514546, 514560, 562400, 562579, 562512, 554 82, 554227, 554230

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraenoic acid (DTAn-6: C22:4n-6) as substrates for the production of novel oxylipins, and to the oxylipins produced thereby. Also disclosed is the use of DPAn-6, DPAn-3, DTAn-6, and/or the oxylipins derived therefrom, and/or novel docosanoids derived from the structures of C22 fatty acids, in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. The invention also relates to novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of LCPUFA-derived oxylipins, and particularly, docosanoids.

7893106, Feb 22, 2011

Jan 31, 2007

11/669730

Linda Mary Arterburn - Ellicott City MD, US
William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Colorado Springs CO, US
Jung Lee - McLean VA, US
Dutt Vinjamoori - Chesterfield MO, US

Martek Biosciences, Corporation - Columbia MD

A61K 31/22
C07C 57/00
C07C 59/00

514549, 514164, 514171, 514560, 562579, 562512, 562400, 554230, 554224, 554227

Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUFA)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

20060247314, Nov 2, 2006

Jun 3, 2005

11/145359

Xiaoli Chen - Belle Mead NJ, US
Keith Demarest - Flemington NJ, US
Jung Lee - McLean VA, US
Jay Matthews - Lansdale PA, US
Philip Rybczynski - Branchburg NJ, US

A61K 31/195
C07C 313/24

514562000, 562428000

The invention features tetralin and indane compounds, compositions containing them, and methods of using them as PPAR alpha modulators to treat or inhibit the progression of, for example, dyslipidemia.

20090023808, Jan 22, 2009

Jun 27, 2008

12/163555

Krishna Raman - Wilmington DE, US
Jung Lee - McLean VA, US
Neil Leininger - Winchester KY, US
Chris Luigart - Lexington KY, US

MARTEK BIOSCIENCES CORPORATION - Columbia MD

A61K 31/23
A61P 25/28
C11C 1/00

514549, 554167, 554 9

The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation.

20090320148, Dec 24, 2009

Jan 31, 2007

12/162945

William Barclay - Boulder CO, US
Bindi Dangi - Elkridge MD, US
James Flatt - Baltimore MD, US
Jung Lee - Mclean VA, US
Dutt Vinjamoori - Chesterfield MO, US

MARTEK BIOSCIENCES CORPORATION - Columbia MD

A01K 67/033
A01K 67/027
A01H 5/00
A01H 13/00
C12N 1/15
C12N 1/13
C07C 61/08
C07C 57/02
A61K 31/19
A61K 31/202
A61P 35/00

800 13, 800 20, 800298, 800296, 43525411, 4352572, 562400, 554224, 514557, 514560

Disclosed are novel oxylipins that are derived from γ-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as anti-inflammatory or anti-neurodegenerative compounds. Also disclosed are The invention novel ways of producing long chain polyunsaturated acid (LCPUF A)-rich oils and compositions that contain enhanced and effective amounts of SDA- and/or GLA-derived oxylipins.

20100130608, May 27, 2010

Oct 1, 2009

12/572263

Alan Stuart RYAN - Ellicott City MD, US
Edward B. Nelson - Austin TX, US
Jung Lee - McLean VA, US
Krishna Raman - Wilmington DE, US

Martek Biosciences Corporation - Columbia MD

A61K 31/22
A61K 31/202
A61P 3/00

514549, 514560

The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w/w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject.